Glaucoma Today

Glaucoma Today Glaucoma Today delivers information on recent research, surgical techniques, clinical strategies, therapeutics, and technology. A BMC Vision publication.

GT offers readers balanced coverage of the topics that matter most! Glaucoma Today is mailed bimonthly (six times a year) to 11,121 glaucoma specialists, general ophthalmologists, and clinical optometrists who treat patients with glaucoma. The publication profiles leaders in the field of glaucoma, and contributing authors present challenging cases as a source of education for readers. Glaucoma Tod

ay delivers balanced coverage of the topics that matter most. Twitter: https://twitter.com/GlaucomaToday
Instagram: https://www.instagram.com/glaucomatoday/

03/24/2025

In this episode of MIGS Unplugged, Dr. Davinder Grover recaps his presentation from the AGS annual meeting on interventional valve-enhancing trabeculotomy (IVENT). Learn more about the mechanisms of action of this procedure and its potential outcomes: https://ow.ly/xvey50VnBsb

03/19/2025

Dr. Ticiana De Francesco recaps her presentation from AGS on findings from the HORIZON study, comparing eyes that underwent phaco and Hydrus implantation with eyes that underwent standalone phaco. See the full video here: https://ow.ly/Tqz450VkQos

Improving ophthalmic care in low-resources settings requires innovation, determination, and dedication. One physician wh...
03/17/2025

Improving ophthalmic care in low-resources settings requires innovation, determination, and dedication. One physician who exemplifies these traits is Sunil Thakali, MD, a comprehensive ophthalmologist and chief of the Hetauda Community Eye Hospital (HCEH) in Hetauda, Nepal.

This article spotlights his journey to becoming a physician against incredible odds and his tireless passion for creating a healthier community for his people: https://ow.ly/8ztH50VjwXs

The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glauc...
03/13/2025

The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers.

This comes as Monday kicked off World Glaucoma Week, during which the Preservative Freedom Coalition is encouraging greater discussion around preservative-free options for patients: https://ow.ly/KZHe50Vgwfk

On World Glaucoma Day, we at Glaucoma Today are honored to collaborate with the glaucoma specialists advancing patient c...
03/12/2025

On World Glaucoma Day, we at Glaucoma Today are honored to collaborate with the glaucoma specialists advancing patient care, the individuals impacted by this disease, and the industry partners driving innovation in the field. Together, we’re working toward a brighter future for those affected by glaucoma.

Want to hear firsthand how this disease impacts patients’ lives? Explore their powerful stories here: https://ow.ly/ZQcj50VgL5p

03/10/2025

The iDose TR from Glaukos has been a new tool in our glaucoma armamentarium since 2024. The placement of the implant is intuitive: direct pressure into the scleral wall. Sometimes, however, the implant may not be securely anchored after being released from the delivery handpiece.

In conjunction with Epsilon surgical instruments, we've designed a simple but elegant device to stabilize the iDose in cases of unstable implantation. Continue watching here: https://bit.ly/4bDMcEM

A 68-year-old man presents for routine glaucoma care. The patient has severe glaucoma that is worse in the left eye. Eig...
03/05/2025

A 68-year-old man presents for routine glaucoma care. The patient has severe glaucoma that is worse in the left eye. Eight years ago, he underwent a trabeculectomy with an Ex-Press glaucoma filtration device (Alcon) in the right eye.

One year ago, a Xen Gel Stent (AbbVie) was implanted in the left eye. His current drug regimen consists of a fixed combination of dorzolamide and timolol administered twice daily in the left eye. Continue reading this editorial here: https://bit.ly/3XvGr6d

03/03/2025

In this issue of Glaucoma Today, contributors take assigned stances to explore whether certain procedures are ready for prime time.

Such deliberations help us to consider all aspects of and viewpoints on glaucoma care and shed light on potential areas where further investigation is needed, continue on at glaucomatoday.com

02/28/2025

Catherine Johnson, MD, MPH, recaps her article, “Impact of Selective Laser Trabeculoplasty on Diurnal IOP Fluctuation,” which was written with Barbara Wirostko, MD, FARVO, and featured in the November/December issue of Glaucoma Today. Home tonometry data are shedding light on SLT’s effect on IOP spikes in the months following laser treatment. This article reviews diurnal IOP fluctuation before and after SLT and discusses the implications of home tonometry in research: https://bit.ly/41dayjO

Join Sight Sciences at   for an engaging lineup of interactive experiences, expert-led discussions, hands-on technology ...
02/27/2025

Join Sight Sciences at for an engaging lineup of interactive experiences, expert-led discussions, hands-on technology demonstrations, and peer-to-peer conversations. Take advantage of this opportunity to ask questions and explore the latest in clinical studies, reimbursement, and other insights. Learn more at sightsciences.com/ags!

__________

All presenters are paid consultants of Sight Sciences. The OMNI Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit sightsciences.com/omni for the indications for use, contraindications, warnings, and potential adverse events.

02/24/2025

Glaukos announced it has received notification from the FDA acknowledging the previously submitted new drug application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus:

Glaukos announced it has received notification from the FDA acknowledging the previously submitted new drug application (NDA) for Epioxa&nbs

"Building a successful practice as a glaucoma specialist involves navigating a lot of new territory beyond the OR, from ...
02/20/2025

"Building a successful practice as a glaucoma specialist involves navigating a lot of new territory beyond the OR, from getting the types of cases you want to understanding reimbursement. In this article, I delve into the topic of building a viable practice and answer some frequently asked questions about the buy-and-bill model and adopting new technology." - Laurie Brown, MBA, COMT, COE, CPC, CPMA, LSSYB Continue reading here: https://bit.ly/416ycyr

02/13/2025

Dr. Kaweh Mansouri reviews placement pearls for MINIject to minimize complications and risk, and discusses safety and efficacy data for the procedure: https://bit.ly/405mDqS

A 68-year-old White woman with a history of severe primary open-angle glaucoma was referred for an evaluation. Her BCVA ...
02/12/2025

A 68-year-old White woman with a history of severe primary open-angle glaucoma was referred for an evaluation. Her BCVA was 20/20 OU, and her IOP measured 14 mm Hg OU with Goldmann applanation tonometry.

Central corneal thickness was 556 µm OD and 544 µm OS. Humphrey visual field testing (Carl Zeiss Meditec) demonstrated dense superior arcuate defects and possible central involvement in both eyes. OCT imaging showed significant retinal nerve fiber layer loss, with superior, inferior, and temporal thinning of both optic nerves.

Read more from this editorial from Nikhila Khandwala, MS, MD, and Ahmad A. Aref, MD, MBA here: https://bit.ly/3EAYmlz

From the early days of their medical training, physicians learn the principle to do no harm and are encouraged to avoid ...
02/06/2025

From the early days of their medical training, physicians learn the principle to do no harm and are encouraged to avoid conducting invasive procedures unless they are medically necessary.

The default approach is, in the absence of an acute emergency, to rely on medical management first before turning to surgery.

Since the advent of selective laser trabeculoplasty (SLT), however, the traditional glaucoma treatment paradigm has been shifting. Continue reading this article from Catherine Johnson, MD, MPH, and Barbara Wirostko, MD, FARVO here: https://bit.ly/4gvJbax

02/04/2025

N. Troy Gurney, MD, and Richard K. Lee, MD, PhD, recap their article, “Pearls for Effective Laser Cyclophotocoagulation of the Glaucomatous Eye,” which was featured in a recent issue of Glaucoma Today. They make the case that transscleral cyclophotocoagulation should be considered earlier in the glaucoma treatment algorithm and review the proper technique and indications to maximize effectiveness and minimize complications: https://bit.ly/4jCVrZH

This retrospective cohort study assessed whether future rapid visual field (VF) worsening could be predicted with the us...
01/31/2025

This retrospective cohort study assessed whether future rapid visual field (VF) worsening could be predicted with the use of deep learning models (DLMs). A total of 4,536 eyes from 2,962 patients monitored for glaucoma or suspected glaucoma were evaluated.

Eight DLMs were trained on baseline clinical data, including age, s*x, BCVA, and IOP; OCT data; and VFs, including reliability data and mean deviation.

Read more on this issue from Julius T. Oatts, MD, and Ying Han, MD, PhD here: https://bit.ly/40SOHiS

Address

Wayne, PA

Alerts

Be the first to know and let us send you an email when Glaucoma Today posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Glaucoma Today:

Videos

Share

Category